1250 - Testing of the ALK gene in tumour material from patients with non-small cell lung cancer to determine eligibility for treatment with crizotinib

Page last updated: 12 October 2016

Application Detail



Description of Medical Service

ALK FISH testing identifies tumours that carry the ALK rearrangement obtained from patients with advanced NSCLC. Subsidy from the Pharmaceutical Benefits Scheme is also being sought for crizotinib for the treatment of patients with the ALK rearrangement.

Description of Medical Condition

ALK-positive advanced NSCLC.

Reason for Application


Medical Service Type


Previous Application Number

Not Applicable

Associated Documentation

Application Form


PICO Confirmation

Final Decision Analytic Protocol (DAP) (PDF 585 KB)
Final Decision Analytic Protocol (DAP) (Word 6128 KB)

Assessment Report


Public Summary Document

Public Summary Document (PDF 247 KB)
Public Summary Document (Word 150 KB)

Meetings for this Application


12 – 13 April 2012
16 – 17 August 2012


10 – 11 October 2013


28 November 2013